Eric Hurwitz to Bone Morphogenetic Protein 2
This is a "connection" page, showing publications Eric Hurwitz has written about Bone Morphogenetic Protein 2.
Connection Strength
0.671
-
Carragee EJ, Chu G, Rohatgi R, Hurwitz EL, Weiner BK, Yoon ST, Comer G, Kopjar B. Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis. J Bone Joint Surg Am. 2013 Sep 04; 95(17):1537-45.
Score: 0.120
-
Weiner BK, Hurwitz EL, Schoene ML, Carragee EJ. Moving forward after YODA. Spine J. 2013 Sep; 13(9):995-7.
Score: 0.120
-
Comer GC, Smith MW, Hurwitz EL, Mitsunaga KA, Kessler R, Carragee EJ. Retrograde ejaculation after anterior lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a 10-year cohort controlled study. Spine J. 2012 Oct; 12(10):881-90.
Score: 0.113
-
Carragee EJ, Baker RM, Benzel EC, Bigos SJ, Cheng I, Corbin TP, Deyo RA, Hurwitz EL, Jarvik JG, Kang JD, Lurie JD, Mroz TE, Oner FC, Peul WC, Rainville J, Ratliff JK, Rihn JA, Rothman DJ, Schoene ML, Spengler DM, Weiner BK. A biologic without guidelines: the YODA project and the future of bone morphogenetic protein-2 research. Spine J. 2012 Oct; 12(10):877-80.
Score: 0.113
-
Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J. 2011 Jun; 11(6):471-91.
Score: 0.103
-
Carragee EJ, Mitsunaga KA, Hurwitz EL, Scuderi GJ. Retrograde ejaculation after anterior lumbar interbody fusion using rhBMP-2: a cohort controlled study. Spine J. 2011 Jun; 11(6):511-6.
Score: 0.102